New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates

Douglas E. Vaughan*, Joseph Loscalzo

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

1 Scopus citations


The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an "ideal" thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.

Original languageEnglish (US)
Pages (from-to)36-39
Number of pages4
JournalTrends in Cardiovascular Medicine
Issue number1
StatePublished - 1991

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates'. Together they form a unique fingerprint.

Cite this